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Abstract 
Background:  Studies  on  the  cholesterol  lowering  activity  of  tocotrienols  have  yielded  mixed 
results, with some showing cholesterol lowering effect while some showing no activity.  
 
Aim:  A  randomized,  doubleblind,  parallel  group  study  was  conducted  to  investigate  the 
cholesterol lowering activity of tocotrienols.  
 
Methods:  Thirtytwo  hypercholesterolemic  subjects  were  randomly  assigned  to  orally  receive 
either 300 mg of mixed tocotrienols capsules daily or placebo capsules containing 300 mg of soya 
bean oil for a period of 6 months. The subjects were monitored before supplementation and monthly 
thereafter for their serum cholesterol as well as tocotrienol and tocopherol concentrations.  
 
Results: The serum total cholesterol and low density lipoprotein (LDL) cholesterol of the subjects 
in the tocotrienol supplementation group were decreased significantly by 8.9 ± 0.9% and 12.8 ± 
2.6% respectively after 4 months of supplementation and the reduction persisted till the end of the 
6-month study, with a reduction of 10.8 ± 1.0% and 17.3 ± 1.8%, respectively from baseline. 
Moreover, there was a 22fold increase in the total tocotrienol concentrations from baseline during 
supplementation compared to the placebo group, while the concentration of tocopherol recorded 
only a modest increase. On the other hand, the serum cholesterol, total tocotrienol and tocopherol 
concentrations of subjects in the placebo group remained essentially unchanged.  Functional Foods in Health and Disease: 3:106-117                                                                           Page 107 of 117 
   
 
Conclusions: Supplementation with mixed tocotrienols at dose of 300 mg per day resulted in the 
lowering of the serum total and LDL cholesterol levels after 5 months of supplementation. 
 
Keywords: tocotrienols, cholesterol-lowering, total cholesterol, LDL cholesterol, tocopherols 
 
Background 
Tocotrienols are compounds belonging to the vitamin E family and are found abundantly in palm oil 
and cereal grains. They are structurally quite similar to tocopherols and differ only in having an 
unsaturated isoprenoid side chain rather than a saturated phytyl tail [1,2]. Besides being a potent 
chain-breaking  anti-oxidant  [3],  an  increasing  number  of  studies  have  shown  that  tocotrienols 
possess additional beneficial pharmacological actions such as inhibition of platelets aggregation, 
inhibition of monocytic adhesion [1], anti-tumor or chemopreventive property [4,5], neuroprotective 
activity [6], hypoapolipoprotein B property
 [7] as well as cholesterol lowering activity [8]. 
Of the above, the hypocholesterolemic activity of tocotrienols has received much attention 
due mainly to the well-established mechanism of cholesterol suppressive action. The cholesterol 
lowering activity of tocotrienols is ascribed to the ability of the side chain of tocotrienols to increase 
cellular farnesol, which in turn signals the proteolytic degradation of 3-hydroxy-3-methyl-glutaryl-
CoA (HMG-CoA) reductase, the enzyme responsible for the production of cholesterol [9].  
Several  studies  have  been  conducted  to  investigate  the  cholesterol  lowering  activity  of 
tocotrienols in hypercholesterolemic human subjects with mixed results. Two studies by Qureshi et 
al
  [10,11]
  showed that supplementation with  200 mg of mixed or pure tocotrienols  in  subjects 
restricted to a controlled (NCEP Step I) diet led to a reduction of 8-16% of total cholesterol and 
LDL cholesterol within 4 weeks. Moreover, studies conducted without dietary control also showed 
similar results with significant reduction in total cholesterol and LDL cholesterol [8,12]. However, 
there are other studies reported in the literature [13-15], which showed that supplementation with up 
to 240 mg of tocotrienols did not result in lowering of the serum cholesterol. The discrepancy might 
be  due  to  differences  in  the  composition  of  the  supplements  as  well  as  differences  in  the 
bioavailability of dosage forms used. For example, a high -tocopherol content (30% and above) in 
the  tocotrienol  supplement  has  been  found  to  attenuate  the  cholesterol  lowering  activity  of  -
tocotrienol [16] as well as reducing the oral bioavailability of the tocotrienols [17]. The product 
used by Wahlqvist et al [13] had a tocopherol content of 30% while that used by Mensink et al 
[14] had more than 35% tocopherol, and this might explain the absence of cholesterol lowering 
activity observed. On the other hand, the study by Mustard et al [15] was conducted over 28 days 
only and a longer period might be required to see the cholesterol lowering activity. Moreover, the 
bioavailability of lipid soluble drugs was reported to be greatly influenced by the type and volume 
of  oil  administered  concomitantly
  [18]  as  well  as  the  delivery  systems  used
  [19].  Thus,  a 
formulation  that  gives  both  consistent  and  enhanced  absorption  of  the  tocotrienols  will  be 
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In consideration of the above factors that might affect the activity of the tocotrienols, the 
present study was thus conducted to investigate the effects of mixed tocotrienols on the serum 
cholesterol of hypercholesterolemic subjects using a preparation with a mixed tocotrienols content 
greater than 75% with respect to tocopherol and delivered as a self emulsifying formulation to 
facilitate the absorption of tocotrienols.  
 
Methods 
Study Population 
Thirty-two hypercholesterolemic but otherwise healthy subjects (20 males and 12 females) aged 
between  31  and  53  were  recruited  into  the  study.  They  all  had  an  initial  baseline  serum  total 
cholesterol concentrations of  6.2 mmol/L, LDL cholesterol  4.0 mmol/L and triacylglycerol  
3.8 mmol/L. Subjects were considered to be healthy based on an interview regarding their medical 
history. They were excluded from the study if their fasting serum total cholesterol concentrations 
were less than 6.2 mmol/L, body mass indexes of more than 30.0, known history of diabetes or 
having liver, renal and hypertensive diseases. Subjects who were taking (or within the previous 2 
months) cholesterol lowering drugs or medications that have an effect on blood lipid profiles were 
also excluded. All subjects were briefed on the nature of the study and they were required to sign an 
informed consent statement prior to the commencement of the trial.  
 
Experimental Design 
The study was conducted according to a doubleblind, placebocontrolled, parallel group design. 
Prior to the start of the study, the subjects were monitored for a period of two weeks (baseline 
period). Subjects were then randomly assigned to one of the two groups (16 per group) to receive 
either  the  mixed  tocotrienols  supplements  or  placebo  for  a  period  of  6  months  (24  weeks 
supplementation period).   
Subjects were advised to maintain their usual diet as well as physical activity and lifestyle 
throughout  the  study  period.  They  were  also  not  allowed  to  take  drugs  which  were  known  to 
interfere with the blood lipid profiles and to refrain from additional vitamin E supplementation. Any 
signs of illnesses, medications taken, adverse reactions and deviations from protocol were recorded 
in diaries and reported to the investigators during their visits. A 24hour recall of food intake was 
also conducted on each subject for at least thrice during the course of the study to make sure that 
they did not change their dietary pattern. The study procedures were approved by a Joint School of 
Pharmaceutical  Sciences,  University  of  Science  Malaysia/Penang  Hospital  Institutional  Review 
Board. The clinical trial was conducted according to Good Clinical Practice guidelines and the 
Declaration of Helsinki.  
 
Dietary Supplements 
During the supplementation period, subjects assigned to the placebo group were given soft gelatin 
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mixed  tocotrienols  formulated  in  a  selfemulsifying  drug  delivery  system  (Tocovid  Suprabio
, 
Hovid Sdn Bhd, Malaysia). Each soft gelatin capsule contained 50 mg of mixed tocotrienols (30.8% 
tocotrienol,  56.4%  tocotrienols  and  12.8%  tocotrienol).  It  also  contained  22.9  IU  of 
tocopherol.  
The subjects were asked to take three capsules of the placebo or mixed tocotrienols after 
breakfast  and  another  three  at  night  after  their  dinner.  Thus,  the  total  daily  intake  of  mixed 
tocotrienols for each subject was 300 mg. The capsules were provided on a monthly basis during 
each  visit  and  compliance  with  the  supplementation  regimen  was  monitored  by  counting  the 
capsules  that  were  left  over  at  the  end  of  the  month  and  through  questionnaires  given  to  the 
subjects. 
 
Measures  
Initial measures that were obtained included subjects' height, weight, blood pressure, and history of 
significant diseases, medications and alcohol use. Prior to the supplementation (baseline period), 
venous  blood  samples  of  10  ml  volume  each  were  drawn  twice  at  two  weeks  apart  after  an 
overnight fast for determination of their cholesterol profiles and the mean were taken as the baseline 
data. The blood samples were left to clot for approximately 30 minutes before centrifuged. The 
serum was promptly separated and kept frozen at –20°C until analysis. The venous blood samples 
were analysed for total cholesterol, high density lipoprotein (HDL) cholesterol, LDL cholesterol, 
triacylglycerol,  tocotrienol,  tocotrienol,  tocotrienol  and  tocopherol.  During  the  study 
period of 24 weeks, the subjects were also monitored for the above parameters after every 4 weeks 
of supplementation. All the blood samples were collected in the morning after an overnight fast. 
The body weight and blood pressure of the subjects were also recorded during each visit.  
 
Analytical Method 
The serum was analysed enzymatically for total cholesterol, HDL cholesterol and triacylglycerol 
within 1 week after collection using an autoanalyzer (550 Express Plus
, Ciba-Corning, USA). The 
concentrations of LDL cholesterol were then calculated according to the methods of Friedewald et 
al
 [20]. The serum was analysed again in a batch for each subject at the end of the trial. The results 
obtained  from  both  measurements  were  closely  similar  and  the  mean  values  of  the  two 
measurements were subsequently used for the statistically analysis. 
The concentrations of tocotrienol, tocotrienol and tocotrienol in the serum obtained 
from the subjects were determined as a block at the end of the trial using a high performance liquid 
chromatography (HPLC) method with fluorescence detection [21]. On the other hand, the levels of 
tocopherol  in  the  serum  was  determined  using  the  HPLC  method  with  ultraviolet  detection 
reported by Julianto et al
 [22]. 
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Statistical Analysis 
The  data  collected  at  baseline  and  during  the  supplementation  period  for  both  groups  were 
compared using an analysis of variance procedure (ANOVA) for a two factor repeated measures 
split-plot experimental design [23]. If a statistically significant difference was observed, a post-hoc 
simple main effects test was employed to locate the pair that gave rise to the difference observed.  
The  homogeneity  of  the  baseline  characteristics  between  the  two  groups,  namely  age, 
weight, body mass index and the cholesterol levels was assessed using an independent Student's 
ttest. A statistically significant difference was considered at p < 0.05.  
 
Results  
It was estimated that a sample size of 16 subjects per group was required to achieve a statistical 
power of 80% for detecting a 10% change in the serum total cholesterol, being similar to that 
reported by Mustard et al [15] in their study which also investigated the effect of tocotrienols on the 
serum cholesterol.  
 
Table 1. Baseline characteristics of study subjects 
  Tocotrienol Supplementation 
(Mean ± SD) 
Placebo 
(Mean ± SD) 
Age (years)  43.2 ± 5.6  44.8 ± 8.9 
Weight (kg)  76.1 ± 10.8  66.3 ± 7.1 
BMI (kg/m
2)  26.7 ± 3.1  24.5 ± 3.4 
Total Cholesterol (mmol/L)  6.9 ± 0.5  6.9 ± 0.6 
LDL Cholesteroln (mmol/L)  4.8 ± 0.7  4.6 ± 0.6 
HDL Cholesterol (mmol/L)  1.3 ± 0.3  1.4 ± 0.3 
Triacylglycerol (mmol/L)  1.9 ± 0.7  1.8 ± 0.9 
 
All 32 subjects enrolled into the study completed the entire 6 month course (72 weeks). 
There  was  no  dropout,  exclusion  or  withdrawal  of  consent  from  the  subjects  during  the  study 
period. Both treatment groups had equal numbers of male and female patients, each consisting of 
three  females  and  thirteen  males  with  age  ranging  from  31  to  62  years  old.  There  was  no 
statistically  significant  difference  in  any  demographic  characteristics  between  the  two  groups, 
namely, age, weight, body mass index and ethnicity (table 1). Moreover, the initial cholesterol 
levels  in  both  treatment  groups were comparable and no statistically significant  difference was 
detected. 
Compliance  with  the  study  protocol  and  supplementation  regimen  was  satisfactory,  as 
evidenced  by  the  maintenance  of  body  weight  throughout  the  study  period  and  capsule  counts 
during their monthly visit.  No severe adverse drug reaction related to the administration of the drug 
product and placebo was recorded, thus indicating that long term administration of 300 mg of mixed 
tocotrienols for up to 6 months was tolerable among the subjects. 
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Table 2. Mean (± SEM) fasting serum lipids at baseline and after supplementation (mmol/l) 
  Tocotrienol Supplementation (month)    Placebo (month) 
    Baseline  1st  2nd  3rd  4th  5th   6th     Baseline  1st  2nd  3rd  4th  5th   6th  
Total 
Cholesterol 
 
6.91 
(0.11) 
6.93 
(0.15) 
6.85 
(0.16) 
6.90 
(0.14) 
6.74 
(0.14) 
6.29 
(0.13) 
6.17 
(0.13) 
  6.89 
(0.14)  
6.76  
(0.21) 
6.93  
(0.18) 
6.74 
(0.27) 
6.88 
(0.29)  
6.73 
(0.20)  
6.78 
(0.23)  
                                 
LDL cholesterol  
 
4.82 
(0.17) 
4.83 
(0.17) 
4.77 
(0.19) 
4.70 
(0.15) 
4.52 
(0.15) 
4.20 
(0.17)  
3.99 
(0.16) 
  4.59  
(0.16) 
4.60 
(0.14)  
4.59  
(0.25) 
4.64  
(0.25) 
4.68  
(0.23) 
4.62 
(0.20)  
4.61  
(0.20) 
                                 
HDL cholesterol   1.34 
(0.07) 
1.30 
(0.08) 
1.32 
(0.09) 
1.30 
(0.07) 
1.39 
(0.10) 
1.43 
(0.11) 
1.33 
(0.06) 
  1.39 
(0.07) 
1.37  
(0.10) 
1.37  
(0.11) 
1.31  
(0.09) 
1.33  
(0.08) 
1.38  
(0.09) 
1.33  
(0.09) 
                               
LDL: HDL 
Ratio 
3.59  3.72  3.62  3.62  3.25  2.94  3.00    3.30  3.36  3.35  3.54  3.52  3.35  3.47 
                               
TC: HDL Ratio  5.16  5.33  5.19  5.31  4.85  4.40  4.64    4.96  4.93  5.06  5.15  5.17  4.87  5.09 
                               
Triacylglycerids  
 
1.88 
(0.17) 
1.90 
(0.12) 
1.92 
(0.14) 
1.98 
(0.17) 
1.91 
(0.13) 
1.82 
(0.13) 
1.84 
(0.16) 
  1.76 
(0.23)  
1.89 
(0.21)  
1.90 
(0.28) 
1.89 
 (0.26) 
1.81  
(0.23) 
1.84  
(0.19) 
1.83  
(0.18) 
 
 
Mean  concentrations  of  the  fasting  serum  cholesterol  d uring  the  baseline  and 
supplementation period are shown in table 2. It is apparent that significant lowering of the total and 
LDL cholesterol was only observed after more than 4 months (16 weeks) of supplementation with 
the mixed tocotrienols. The total and LDL cholesterol reduction from the baseline values were more 
substantial at the 5
th month, being 8.9 ± 0.9% (p < 0.05) and 12.8 ± 2.6%, respectively. At the 6
th 
month, the two parameters showed a further reduction to 10.8 ± 1.3% (p < 0.05) and 17.3 ± 1.8% (p 
< 0.05), respectively.  In contrast, subjects in the placebo group recorded negligible changes in their 
total and LDL cholesterol concentrations from the baseline throughout the 6months (24 weeks) of 
supplementation. Moreover, significant differences between the two treatment groups for the total 
and LDL cholesterol values were observed at the 5
th and 6
th month (p < 0.05) but not during the first 
four months. It should be emphasised that the total and LDL cholesterol values of all subjects in the 
mixed tocotrienols supplementation group showed a decrease after 4 months of supplementation Functional Foods in Health and Disease: 3:106-117                                                                           Page 112 of 117 
   
 
and no poor respondent (serum cholesterol fell by less than 3%) was identified.  On the other hand, 
the triacylglycerol and HDL cholesterol levels of the subjects in both treatment groups did not 
change significantly during the supplementation period.  
Nevertheless,  as  shown  in  Table  2,  there  was  a  significant  difference  between  the  two 
supplemented groups in terms of reduction in the TC:HDL ratio from baseline, being 14.7% and 
10.1%  at  5th  &  6th  month,  respectively  observed  with  tocotrienol  supplementation  while  the 
placebo group showed a minimal reduction of 1.8% from baseline at 5th month and a slight increase 
of 2.6% from baseline at 6th months. A similar trend was also observed with LDL:HDL ratio. There 
was a significant difference between the two supplemented groups in terms of reduction in the 
LDL:HDL ratio from baseline, being 18.1% and 16.4% at 5th & 6th month, respectively observed 
with tocotrienol supplementation while the placebo control group showed a slight increase of 1.5% 
from baseline at 5th month and a slight increase of 5.2% from baseline at 6th months. 
Overall,  the  concentrations  of  total  tocotrienols  (,    and  tocotrienol)  were  markedly 
higher in the serum of subjects who consumed mixed tocotrienols supplementation compared to 
those in the placebo group (Figure 1). While a 22fold increase in the total serum tocotrienol level 
(from  the  baseline  concentration)  was  recorded  for  the  treatment  group  after  6  months  of 
supplementation, there was no appreciable increase in the placebo group.  As for the individual 
isomers, the highest increment was observed with  tocotrienol, followed by tocotrienol and 
tocotrienol  (data  not  shown).  Ikeda  et  al
  (24)  reported  that  tocotrienol  was  preferentially 
absorbed  compared  to    and  tocotrienols.  Similarly,  Yap  [17]
  also  reported  that  the  oral 
bioavailability of the tocotrienol was higher than that of the other two isomers. 
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Fig. 1. Mean (±SEM) plasma total tocotrienols concentration after 
supplementation with placebo and mixed tocotrienols
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Fig. 1. Mean (±SEM) plasma total tocotrienols concentration after supplementation with placebo 
and mixed tocotrienols.  █  = tocotrienol supplementation,   = placebo 
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Fig. 2. Mean (±SEM) plasma tocopherol concentrations after supplementation with placebo and 
mixed tocotrienols.  █  = tocotrienol supplementation,   = placebo 
 
Referring to figure 1, it can also be seen that a marked increase in the mean total tocotrienol 
level was evident after the first month of supplementation, reaching a plateau after the 3
rd month 
while that of the placebo group remained essentially unchanged throughout the study period.  
Figure 2 shows the mean tocopherol levels of the two groups over the study period. It can 
be seen that the tocopherol levels in the mixed tocotrienols supplementation group was slightly 
increased after the first month of supplementation and remained essentially unchanged thereafter. 
The increase was approximately 20% from the baseline, being markedly less than that observed 
with the total tocotrienols. On the other hand, the subjects in the placebo group did not record any 
appreciable increase in the tocopherol concentration.  
 
Discussion 
The results of this study show that a reduction in the total and LDL cholesterol was observed after 4 
months (16 weeks) of daily supplementation with 300 mg of mixed tocotrienols, while the HDL 
cholesterol  and  triacylglycerol  levels  remained  essentially  unchanged.  The  results  obtained  are 
consistent with those reported by Qureshi et al [8,10,11]
 and Tan et al [12], although the dosage and 
duration of tocotrienol supplementation, diet control as well as magnitude of cholesterol reduction 
varied from the present study.  
In addition, it is also evident that there was a significant reduction in the ratio of TC:HDL 
after 4 months of tocotrienol supplementation as compared to the placebo group. TC:HDL ratio 
which contains both an atherogenic and antiatherogenic lipid component, has been accepted as a 
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an increased risk of ischemic stroke [25]. Furthermore, a significant reduction in LDL:HDL ratio 
can be also be observed with the tocotrienol supplemented group. In comparison, the placebo group 
did not show a similar reduction in LDL:HDL ratio. Instead, a slight increase in the ratio was 
observed.  Low  level  of  LDL-cholesterol  has  traditionally  been  associated  with  reduced  risk  of 
cardiovascular  disease  while  HDL  cholesterol  is  protective  against  cardiovascular  diseases  and 
stroke,  particularly  non-fatal  stroke  and  ischemic  stroke  in  the  elderly  [25].  Hence,  a  lower 
LDL:HDL ratio infers a reduced risk of cardiovascular diseases. 
In  the  present  study,  it  can  be  observed  that  the  reduction  in  serum  cholesterol  in  the 
supplemented  group  was  accompanied  by  a  significant  concomitant  elevation  in  the  serum 
tocotrienol levels, being similar to that observed in the study by Qureshi et al [8]. Moreover, the 
elevation in tocotrienol levels from the baseline values was accompanied by a relatively negligible 
increase  in  the  tocopherol  level.  This,  in  turn,  would  translate  into  a  significant  increase  of 
approximately 18 times in the ratio of tocotrienol to tocopherol levels (T3:T1) after supplementation 
or when compared to the placebo group. A similar observation was also reported by Qureshi et al 
[8].  
As  mentioned  earlier,  inconsistent  cholesterol  lowering  effect  of  tocotrienols  have  been 
reported in the literature. Three studies have shown that supplementation with up to 240 mg per day 
of mixed tocotrienols did not cause a decrease in the serum cholesterol levels [13-15]. In all these 3 
studies, the serum tocotrienol levels were only modestly increased when compared to the baseline 
concentrations or the placebo group. This could be attributed to the poor and erratic bioavailability 
of tocotrienols when administered as a normal lipid formulation. The selfemulsifying formulation 
used in the present study was reported to produce a more consistent as well as enhanced absorption 
of the tocotrienols. In the study by Mustard et al
 [15] in which the mixed tocotrienol preparations 
were taken after meal, the increase in the tocotrienol levels was still relatively small when compared 
to the placebo group although the authors claimed otherwise. The small increment observed could 
also be ascribed to poor subject compliance towards the supplementation regimen. Moreover, the 
duration for tocotrienol supplementation of 4 weeks might not be sufficient to achieve significant 
cholesterol reduction in view of the comparatively small increase in the tocotrienol levels. In the 
present  study,  the  serum  tocotrienol  levels  were  observed  to  increase  even  after  4  weeks  of 
supplementation, reaching a plateau only after 12 weeks.  
Interestingly, the studies by Wahlqvist et al [13], Mensink et al [14] and Mustard et al
 [15] 
(which showed no cholesterol lowering activity) did not display a significant increase in the ratio of 
serum T3:T1 as compared to the study by Qureshi et al [8] that showed hypocholesterolemic effect 
of tocotrienols. This might be due either to the modest increment in the serum tocotrienol levels or 
there was a concomitant increase in the tocopherol levels. Qureshi et al
 [16] has demonstrated that 
tocopherol could attenuate the cholesterol lowering ability of tocotrienols, and this might help 
to explain the absence of hypocholesterolemic activity of tocotrienols in the three studies. Thus, it 
could  be  inferred  that  the  hypocholesterolemic  activity  upon  ingestion  of  mixed  tocotrienol 
preparations  could  only be attained if there was  a significant  increase  in  the serum tocotrienol Functional Foods in Health and Disease: 3:106-117                                                                           Page 115 of 117 
   
 
concentrations  relative  to  the  tocopherol  concentrations.  This  may  account  for  the  discrepancy 
observed in  the cholesterol lowering activity of tocotrienols  among the studies.  In view of the 
erratic  oral  bioavailability  of  the  tocotrienols,  they  might  best  be  given  via  a  suitable  delivery 
system that could ensure more consistent and higher oral bioavailability such that the beneficial 
effects of the tocotrienols could be attained. 
 
Conclusion 
Lowering  of  the  total  and  LDL  cholesterol  levels  in  hypercholesterolemic  subjects  could  be 
achieved through supplementation with mixed tocotrienols, and was accompanied by a significantly 
higher serum tocotrienol concentration relative to the tocopherol level. The cholesterol lowering 
activity can be attained after 4 months of supplementation. 
 
Abbreviations:  Low  density  lipoprotein  (LDL),  High  density  lipoprotein  (HDL),  3-hydroxy-3-
methyl-glutaryl-CoA reductase (HMG-CoA reductase), High performance liquid chromatography 
(HPLC), an analysis of variance procedure (ANOVA), Tocotrienol to tocopherol levels (T3:T1) 
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